深夜！减肥药巨头大涨！

Group 1 - Novo Nordisk's stock rose over 6% and Eli Lilly's stock increased nearly 4% due to a lawsuit against Hims & Hers for infringing on the patent of semaglutide [3][4] - Hims & Hers' stock plummeted over 26% after the announcement of the lawsuit, which claimed that their competing product could pose potential dangers to consumers [3][4] - The FDA has indicated it will restrict the use of GLP-1 active ingredients in unapproved compounded drugs, which has been widely sold as alternatives to original drugs [3][4] Group 2 - Analyst Soren Lontoft Hansen from Sydbank noted that the rise in Novo Nordisk's stock reflects investor optimism regarding the FDA's crackdown on the compounded pharmaceutical industry [4] - The FDA's actions are seen as a direct challenge not only to Hims & Hers' compounded oral medication but also to the entire GLP-1 drug sector, benefiting both Novo Nordisk and Eli Lilly [4] - Since peaking in June 2024, Novo Nordisk's market value has evaporated by nearly two-thirds, with a cumulative decline of almost 50% over the past year [4]